Method for Identification of alpha-Amidated Peptides

Information

  • Research Project
  • 6585350
  • ApplicationId
    6585350
  • Core Project Number
    R43DK063812
  • Full Project Number
    1R43DK063812-01
  • Serial Number
    63812
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/2003 - 21 years ago
  • Project End Date
    3/31/2005 - 19 years ago
  • Program Officer Name
    ARREAZA-RUBIN, GUILLERMO
  • Budget Start Date
    4/1/2003 - 21 years ago
  • Budget End Date
    3/31/2005 - 19 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -

Method for Identification of alpha-Amidated Peptides

DESCRIPTION (provided by applicant): Peptide hormones are ubiquitous in nature, and perform cellular functions that are critical to the survival of the organism. Approximately 50 percent of all known peptide hormones are post-translationally modified at the C-terminus by conversion of glycine-extended precursors to the peptide-amide. The enzyme that performs this modification is peptidylglycine alpha-amidating mono-oxygenase (PAM). Inhibition of PAM in various cell types in culture can be accomplished by the addition of specific PAM inhibitors, such as 4-phenyl-3-butenoic acid, resulting in the accumulation of glycine-extended hormone precursors in the conditioned medium. The medium will be fractionated by chromatography techniques and the individual fractions assayed by sequential enzyme reactions consisting of PAM --> glyoxylate dehydrogenase or PAM > glyoxal oxidase --> horseradish peroxidase, to yield a color reaction. In Phase I, we will optimize the enzyme reactions using model glycine-extended substrates, and demonstrate feasibility by the isolation of known peptide hormones from CA-77 cells using this technology. During Phase II, the optimized technology will be used to detect novel amidated peptide hormones in neuro-endocrine cells, and produce the novel peptides recombinantly to obtain material for a series of physico-chemical and functional characterizations. The success of this project will eventually lead to the development of novel therapeutic peptide drugs.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    123438
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:123438\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIGENE LABORATORIES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    FAIRFIELD
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07004
  • Organization District
    UNITED STATES